Paratek Pharmaceuticals
Founded Year
1996Stage
Take Private | AliveTotal Raised
$129.3MValuation
$0000Revenue
$0000About Paratek Pharmaceuticals
Paratek Pharmaceuticals is a clinical-stage biopharmaceutical company. It develops solutions for adult patients with CABP (Community-Acquired Bacterial Pneumonia) and Acute Bacterial Skin and Skin Structure Infections (ABSSSI) caused by susceptible bacteria. The company was founded in 1996 and is based in Boston, Massachusetts.
Loading...
Loading...
Paratek Pharmaceuticals Patents
Paratek Pharmaceuticals has filed 89 patents.
The 3 most popular patent topics include:
- bacterial diseases
- antibiotics
- designer drugs
Application Date | Grant Date | Title | Related Topics | Status |
|---|---|---|---|---|
2/24/2020 | 9/28/2021 | Bacterial diseases, Rickettsioses, Biological weapons, Enterobacteriaceae, Zoonoses | Grant |
Application Date | 2/24/2020 |
|---|---|
Grant Date | 9/28/2021 |
Title | |
Related Topics | Bacterial diseases, Rickettsioses, Biological weapons, Enterobacteriaceae, Zoonoses |
Status | Grant |
Latest Paratek Pharmaceuticals News
Oct 30, 2023
R-Bridge Healthcare Fund, the private credit & royalty investment arm of CBC Group, Asia’s largest healthcare-dedicated investment firm, focused on providing non-dilutive financing to healthcare companies backed by royalties, revenue interests and other cashflows, has exited commercial-stage biopharmaceutical company Paratek Pharmaceuticals. The exit was realized through an early redemption of the US$60m royalty backed financing […]
Paratek Pharmaceuticals Frequently Asked Questions (FAQ)
When was Paratek Pharmaceuticals founded?
Paratek Pharmaceuticals was founded in 1996.
Where is Paratek Pharmaceuticals's headquarters?
Paratek Pharmaceuticals's headquarters is located at 75 Park Plaza, Boston.
What is Paratek Pharmaceuticals's latest funding round?
Paratek Pharmaceuticals's latest funding round is Take Private.
How much did Paratek Pharmaceuticals raise?
Paratek Pharmaceuticals raised a total of $129.3M.
Who are the investors of Paratek Pharmaceuticals?
Investors of Paratek Pharmaceuticals include Novo Holdings, Gurnet Point Capital, CBC Group, HBM Healthcare Investments, LODH Private Equity Partners and 23 more.
Who are Paratek Pharmaceuticals's competitors?
Competitors of Paratek Pharmaceuticals include Advaxis, Molmed, Potentia Pharmaceuticals, Ampla Pharmaceuticals, Stromedix and 7 more.
Loading...
Compare Paratek Pharmaceuticals to Competitors
Bolder BioTechnology, Inc. uses advanced protein engineering technologies to create human protein pharmaceuticals with enhanced therapeutic properties. Most protein pharmaceuticals are rapidly eliminated by the body, which limits their effectiveness and requires that they be administered by frequent, often daily, injection. The company's products are designed to last longer in the body, which aims to allow them to be administered less frequently, e.g., once per week to once per month, and maximizes their therapeutic benefits to patients. Company scientists combine protein structure/function information with targeted protein modification technologies to rationally design long-acting protein pharmaceuticals that, in many cases, are 10-100-fold more potent than competing products prepared using non-targeted protein modification technologies. Bolder BioTechnology has a robust pipeline of products in preclinical development, including products for the treatment of hematological and endocrine disorders, cancer and infectious disease. The company intend to commercialize these products independently and through strategic alliances with corporate partners.
Spaltudaq is a company that specializes in the construction industry, with a focus on roofing services. The company offers a range of services including roof installation, roof replacement, and roof repair, catering to both residential and commercial needs. These services are designed to ensure the durability and longevity of roofing systems, providing protection and security for buildings. It was founded in 2004 and is based in Seattle, Washington.
Longevica is a biotechnology that is researching mechanisms of healthy aging and life extension. The company is also developing an open research tool for scientists and research institutions to access a data set that tracks the effects of pharmacological compounds for testing drugs.
Arisyn Therapeutics Inc. is a biotechnology company focused on the development of first in class inhibitors of infectious disease and cancer. Arisyn possesses a portfolio of small molecule compounds that will be developed to treat Human Immunodeficiency Virus-Type 1 (HIV-1), Human Immunodeficiency Virus-Type 2 (HIV-2), Human T-Lymphotropic Virus-Type 1 (HTLV-1), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV) and Herpes Simplex Virus-Type 2 (HSV-2). Arisyn will perform all necessary studies required to develop these therapeutic agents through Phase 1 and Phase 2 human clinical trials.
Qwell Pharmaceuticals is a biotechnology company focused on small molecule development primarily for oncology indications.
Abunda, is a stealth mode healthcare company incubated by Burrill & Company
Loading...